Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04994795 · ClinicalTrials.gov registry record
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
A clinical trial of Non Small Cell Lung Cancer Metastatic, sponsored by Sophia Genetics SAS.
- Active
- Registry status
- 4,000
- Enrollment target
- 20
- Study locations
NCT04994795: Active study of Non Small Cell Lung Cancer Metastatic, sponsored by Sophia Genetics SAS.
NCT04994795 is a study of Non Small Cell Lung Cancer Metastatic that is active but no longer recruiting, run by Sophia Genetics SAS. The registered enrollment target is 4,000 participants, above the 187-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (2039% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04994795, a study of Non Small Cell Lung Cancer Metastatic, is active but no longer recruiting, sponsored by Sophia Genetics SAS.
- ACTIVE NOT RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
Primary Outcome
Predict treatment response at first evaluation using baseline data
Conditions Studied
Interventions
- OTHER Predictive models (data collection)
Study Locations (20)
Other
- DASA - Hospital Brasilia - Brasília
- DASA - Hospital de Niteroi - Niterói
- DASA - Hospital São Lucas - Rio de Janeiro
- DASA - Hospital Nove De Julho - São Paulo
- AC Camargo - São Paulo
- Sunnybrook Health Sciences Centre Toronto - Toronto
- Avicenne Hospital - Bobigny
- CHU Bordeaux - Bordeaux
- Ambroise Paré Hospital - Boulogne-Billancourt
- Hospices Civils de Lyon - Lyon
- CHU de Nantes - Nantes
- La Pitié Salpêtrière - Paris
- Tenon Hospital - Paris
- Foch Hospital - Suresnes
Iowa
- Holden Comprehensive Cancer Center at University of Iowa Health Care - Iowa City
Massachusetts
- UMASS Memorial Health - Worcester
Minnesota
- Mayo Clinic - Rochester
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Utah
- Huntsman Cancer Institute - Salt Lake City
Wisconsin
- Carbone Comprehensive Cancer Center at University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2021-08-21 |
| Est. Completion | 2025-02 |
What the registry record for NCT04994795 still lists
NCT04994795 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 187-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (2039% higher).
The record links to 1 condition, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Predictive models (data collection) is the first listed.
NCT04994795 names 20 study sites across 7 states, led by Other, Iowa, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04994795 about?
NCT04994795 is a clinical study titled "Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer". Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
What is the current status of trial NCT04994795?
This trial is currently active not recruiting. The enrollment target is 4,000 participants. The study started on 2021-08-21. Estimated completion is 2025-02.
What conditions does trial NCT04994795 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic.
What interventions are being tested in trial NCT04994795?
The interventions under investigation include: Predictive models (data collection) (OTHER).
Who is sponsoring clinical trial NCT04994795?
This trial is sponsored by Sophia Genetics SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04994795 being conducted?
This trial has 20 study locations across Iowa, Massachusetts, Minnesota, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Small Cell Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04994795's enrollment target sits among peer trials
4,000 1st of 16 higher than 16 of 16 other Non Small Cell Lung Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non Small Cell Lung Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI